Moderna CEO outlines next steps after melanoma vaccine trial success

Moderna CEO outlines next steps after melanoma vaccine trial success

व्यवसाय स्वास्थ्य
इस घटना को पिन करने के लिए साइन इन करें

Moderna chief executive Stéphane Bancel said in New York that the company will present Phase 3 results for its personalized mRNA melanoma therapy intismeran and outlined how the data will shape future research. The Phase 3 trial, conducted jointly with Merck and combined with Keytruda, showed a 42 % reduction in melanoma recurrence or death and cut the risk of distant metastasis by 38 % compared with Keytruda alone. The results met expectations and were reported by multiple outlets, while the companies’ shares fell after the announcement.

अभिनेताओं

Moderna Merck TD Cowen RBC Capital Markets

स्थान

Wall Street, New York, United States

तथ्य जांच

ये मेट्रिक्स कैसे काम करती हैं
फ़ैसला: आंशिक रूप से पुष्ट विश्वास स्तर: 72% दावे: 5
एक नज़र में

One claim stating that a Merck-Moderna mRNA vaccine combined with Keytruda reduced melanoma recurrence or death by 42% in a pivotal study was confirmed. Three claims were partially confirmed: the Moderna-Merck personalized mRNA vaccine intismeran reduced melanoma recurrence and death by 42% when added to Keytruda in a phase III study, Moderna's chief executive Stéphane Bancel noted the upcoming presentation of Phase 3 results for the mRNA melanoma therapy intismeran, and the combined vaccine and Keytruda regimen lowered distant metastasis risk by 38% in patients with resected melanoma. One claim reporting that Merck and Moderna announced on October 22, 2026, that their personalized mRNA vaccine combined with Keytruda reduced the risk of death or recurrence by 42% in patients with resected melanoma had not enough evidence.

पूर्ण विवरण अनलॉक करने के लिए साइन इन करें या सदस्यता लें: दावे, स्रोत और सत्यापन।

रजिस्टर करें साइन इन करें

इस अनुभाग में बाहरी स्रोतों के विरुद्ध दावों का स्वचालित सत्यापन है और इसमें अशुद्धियाँ हो सकती हैं।

लेख

26 अक्टूबर 2026
2 कुल
Moderna CEO on what's next after success in cancer vaccine
Moderna CEO on what's next after success in cancer vaccine

STAT • 26 अक्टू 08:31

Moderna's chief executive Stéphane Bancel highlighted the upcoming presentation of Phase 3 results for the mRNA melanoma therapy intismeran and outlined its implications for the company's research direction.

विश्वसनीयता 72% हेरफेर 8% मध्यस्थ
World-First Cancer Vaccine Cuts Melanoma Recurrence or Death Risk by 42% in Landmark Trial
World-First Cancer Vaccine Cuts Melanoma Recurrence or Death Risk by 42% in Landmark Trial

ScienceAlert • 26 अक्टू 02:01

A phase 3 study of a personalized mRNA vaccine developed by Moderna and Merck showed a 42% reduction in melanoma recurrence or death compared with standard immunotherapy alone.

विश्वसनीयता 78% हेरफेर 32% मध्यस्थ
25 अक्टूबर 2026
2 कुल
Cancer vaccine significantly reduces chance of melanoma patients’ tumours returning, results show
Cancer vaccine significantly reduces chance of melanoma patients’ tumours returning, results show

The Globe and Mail • 25 अक्टू 18:12

A trial of the mRNA-based vaccine intismeran showed a 42% reduction in melanoma recurrence two years after surgery when added to standard therapy.

विश्वसनीयता 78% हेरफेर 12% मध्यस्थ
What's next for cancer vaccines after successful melanoma study
What's next for cancer vaccines after successful melanoma study

STAT • 25 अक्टू 08:34

A Merck-Moderna mRNA vaccine combined with Keytruda lowered melanoma recurrence or death by 42% in a pivotal study, prompting discussion of broader cancer-vaccine applications.

विश्वसनीयता 73% हेरफेर 32% मध्यस्थ
23 अक्टूबर 2026
1 कुल
Personalized mRNA vaccine for melanoma cut risk of cancer’s return in late-stage trial
Personalized mRNA vaccine for melanoma cut risk of cancer’s return in late-stage trial

NBC News • 23 अक्टू 18:42

In a phase III study, the Moderna-Merck personalized mRNA vaccine intismeran reduced melanoma recurrence and death by 42% when added to Keytruda, compared with Keytruda alone.

विश्वसनीयता 71% हेरफेर 32% मध्यस्थ
22 अक्टूबर 2026
2 कुल
Moderna, Merck shares fall on eagerly anticipated cancer vaccine results
Moderna, Merck shares fall on eagerly anticipated cancer vaccine results

BioPharma Dive • 22 अक्टू 22:24

A combined vaccine and Keytruda regimen reduced the relative risk of disease recurrence or death by 42% in advanced melanoma, meeting expectations, while the companies' stocks fell after the announcement.

विश्वसनीयता 71% हेरफेर 8% मध्यस्थ
Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%

Ars Technica • 22 अक्टू 22:12

Merck and Moderna reported that their personalized mRNA vaccine combined with Keytruda reduced the risk of death or recurrence by 42% in patients with resected melanoma, and lowered distant metastasis risk by 38%.

विश्वसनीयता 78% हेरफेर 7% मध्यस्थ

संबंधित घटनाएँ